Articles
Clinical-trial-grounded articles on GLP-1, peptide, and metabolic medications — what's prescribed today, what's coming next, and how to make sense of the science.
The August 12, 2026 lawsuits target med spas, compounding pharmacies, and peptide vendors. Here's who was sued, what Lilly alleges, and what waiting patients need to know.
Neutral, evidence-based guide to TrumpRx direct-to-consumer pricing for Zepbound, Mounjaro, Wegovy, and Ozempic — real 2026 prices, Medicare $50 tier, and enrollment steps.
The 8 evidence-backed levers that separate the top 15% of GLP-1 results from average outcomes — protein, sleep, resistance training, adherence, hydration, and how to break plateaus without chasing a higher dose.
Head-to-head comparison of GLP-1 pills (Foundayo, Wegovy oral, Rybelsus) vs injectable pens (Wegovy, Ozempic, Zepbound) — trial data, cost, side effects, and a clear decision framework.
The Fifth Circuit affirmed the FDA on August 27, 2026 — ending bulk 503B compounding of GLP-1s. Here's what actually changed, what didn't, and three legitimate paths forward.
Starbucks and 6% of large employers cut GLP-1 coverage in 2026. Here are three real paths to stay on Wegovy, Zepbound, Ozempic, or Mounjaro without your insurance.
The Medicare GLP-1 Bridge started July 1, 2026. Full 4-point eligibility checklist, 6-step enrollment guide, and how to check your Part D portal.
Lilly's confirmed Q4 2026 NDA filing intent, the TRIUMPH Phase 3 readout schedule, and three realistic FDA decision scenarios ranging from mid-2027 to early 2028.
A complete guide to GLP-1 injection sites: how to rotate weekly, prevent bruising, spot warning signs, and track everything in the GLPTree app.
Track injections, weight, protein, and side effects — plus 100+ GLP-1 friendly recipes. Free to start. Premium optional.
A 350-calorie, 30g protein breakfast parfait built for Ozempic, Wegovy, and Mounjaro appetites. Exact measurements, why it works, and how to nail your morning protein target.
The FDA warned 16 companies selling retatrutide online. 7 kept selling. Six Australians ended up in acute liver failure. Here's what the July 2026 crackdown means — and your safe legal options.
Oral Wegovy launched in the US at $149/month and hit 3M+ prescriptions. Here's how the pill dosing schedule, pricing tiers, and efficacy compare to injectable Wegovy.
Is compounded semaglutide or tirzepatide still legal in 2026? Here's what the FDA's May proposal actually says, what's already changed, and your real options.
A new Cleveland Clinic study of nearly 8,000 patients found weight regain after stopping GLP-1s is far less severe than earlier trials suggested. Here's why.
A new Gallup survey shows 11% of US adults now use GLP-1 drugs for weight loss, up from 3% in 2024, as obesity rates decline. Here's the full data breakdown.
New Lancet trial data on tirzepatide dose reduction after reaching goal weight: what SURMOUNT-MAINTAIN found about lower maintenance doses vs. stopping.
Hair shedding on Ozempic, Wegovy, or Mounjaro is real but usually temporary telogen effluvium. The mechanism, nutrient checklist, and regrowth timeline.
A new JAMA Network Open study of 1.5 million patients found a 76% relative increase in a rare optic nerve condition tied to semaglutide and tirzepatide.
A new Journal of Medical Toxicology study found GLP-1 poison control calls nearly doubled after FDA weight-loss approval. The two mistakes driving it.
New 2026 research shows semaglutide and tirzepatide have different, nuanced effects on anxiety and depression risk. What the real-world data shows.
Should you do IF on Ozempic, Wegovy, or Mounjaro? Hypoglycemia risk, muscle loss, and an electrolyte protocol that protects results.
Stacking keto with Ozempic, Wegovy, or Mounjaro? Keto-flu meets GLP-1 nausea, muscle preservation, and the keto-rebound risk when titrating off.
Foundayo (orforglipron) FDA approved April 1, 2026 — the first oral GLP-1 pill with no food restrictions. Cost, efficacy, side effects, drug interactions.
Mounjaro, Zepbound, and Foundayo all warn that oral birth control may fail. Safe contraceptive options and exactly how long backup is needed.
GLP-1 users move 11% less per ENDO 2026 data. Resistance training, protein, and ketone ester protocol that preserves 92% of muscle mass.
What clinical trials show happens when you stop GLP-1s — STEP 1 Extension, SURMOUNT-4, and the 2026 meta-analysis — plus a safer off-ramp.
A complete look at the Phase 2 NEJM data (24.2% mean weight loss) and the May 2026 TRIUMPH-1 Phase 3 topline (28.3% at 80 weeks). What the responder rates and unreached plateau actually mean.
The mechanism behind the next generation of metabolic drugs. Why adding glucagon to GLP-1 and GIP increases energy expenditure, not just appetite suppression — and what it means for tolerability and safety.
Side-by-side Phase 2 vs. TRIUMPH-1 Phase 3 dose-escalation schedules, the rationale for the added 6 mg step, and how retatrutide titration compares to tirzepatide and semaglutide.
Why the right Mounjaro comparator is SURMOUNT-1 (obesity) and not SURPASS (T2D), and what the TRIUMPH-5 head-to-head trial will settle by late 2026.
A methodologically rigorous cross-trial comparison of SURMOUNT-1 (tirzepatide, 20.9%) and TRIUMPH-1 (retatrutide, 28.3%) — plus what each methodological difference can and can't explain.
How to meet protein targets when appetite is suppressed on Ozempic or Wegovy. Sample meal patterns, practical tips, and why protein protects muscle.
An honest, evidence-based guide to peptides marketed for fat loss — AOD-9604, tesamorelin, BPC-157, and others — including what evidence exists, legal status, and consumer warnings.
Ozempic and Wegovy are the same molecule — semaglutide — but with key differences in approved dose, indication, insurance, and cost. Here's the full breakdown.
Plain-English guide to next-gen weight loss drugs in late-stage trials: retatrutide, survodutide, cagrisema — what they are, how they work, and what the data shows.
Mounjaro and Zepbound are the same drug — tirzepatide — in different packaging. Here's what determines which you get, and how costs differ.
Evidence-based strategies for managing GLP-1 side effects including nausea, fatigue, constipation, and sulfur burps on Ozempic, Wegovy, or Mounjaro.
Plain-English breakdown of STEP, SURMOUNT, and SCALE trial data — what average weight loss on Wegovy, Mounjaro, and Ozempic looks like in the real world.
Why weight loss plateaus happen on Ozempic, Wegovy, and Mounjaro — the biology behind them, when to expect one, and evidence-based strategies to move forward.
GLP-1 suppresses appetite and drives weight loss. GLP-2 is a gut growth hormone for short bowel syndrome. Learn why GLP-2 is not a weight loss therapy — and what's actually true.
A complete guide to GLP-1 dose escalation — why slow titration exists, what happens at each step on Wegovy, Ozempic, Zepbound, and when to ask about pausing.
Full 2026 breakdown of GLP-1 medication costs with and without insurance — Ozempic, Wegovy, Mounjaro, Zepbound — plus savings cards, GoodRx, and compounding options.
A week-by-week guide to your first month on Ozempic, Wegovy, or Mounjaro — appetite changes, side effects, and what's normal.
How to set calorie and macro targets on Ozempic, Wegovy, or Mounjaro. Why extreme undereating backfires, muscle loss risks, and a practical nutrition framework.
A complete guide to compounded semaglutide and tirzepatide — legal status in 2026, FDA stance, safety differences vs. branded drugs, cost comparison, and what to watch for.
CagriSema Phase 3 data explained — how combining semaglutide with the amylin analog cagrilintide produced 22.7% weight loss, and why amylin matters for obesity treatment.